“…polypeptides ( Fang et al, 2020 ; Kang et al, 2020 ), proteins, antibodies ( Chen et al, 2012 ; Pan et al, 2021 ), folic acids ( Mitra et al, 2018 ) and aptamers ( Tang et al, 2020 ; Tian et al, 2021 )). On this basis, the unique advantages of nanocarriers have been widely demonstrated including long-term sustained ( Xia et al, 2019 ) and controlled release ( Xia et al, 2014 ) and the integration with more diagnostic or therapeutic modality such as multimodal imaging ( Gao et al, 2017 ; Xia et al, 2017 ; Liu et al, 2019 ), photodynamic therapy (PDT) ( Lucky et al, 2015 ; Wen et al, 2020 ), photothermal therapy (PTT) ( Xia et al, 2016 ; Yang et al, 2017 ) and immunotherapy ( Meraz et al, 2012 ; Secret et al, 2013 ). However, the major limitation of nanomedicine lies in the insufficient anticancer therapeutic efficacy, thus there is an urgent demand to further improve their therapy efficacy.…”